SBFM vs. HCWB, FLGC, SNSE, IMNN, BGXX, AIM, HOTH, CRVO, WENA, and RLMD
Should you be buying Sunshine Biopharma stock or one of its competitors? The main competitors of Sunshine Biopharma include HCW Biologics (HCWB), Flora Growth (FLGC), Sensei Biotherapeutics (SNSE), Imunon (IMNN), Bright Green (BGXX), AIM ImmunoTech (AIM), Hoth Therapeutics (HOTH), CervoMed (CRVO), ANEW Medical (WENA), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry.
Sunshine Biopharma vs.
HCW Biologics (NASDAQ:HCWB) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, community ranking, valuation, media sentiment, analyst recommendations, dividends and earnings.
In the previous week, HCW Biologics had 2 more articles in the media than Sunshine Biopharma. MarketBeat recorded 2 mentions for HCW Biologics and 0 mentions for Sunshine Biopharma. HCW Biologics' average media sentiment score of 0.44 beat Sunshine Biopharma's score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media.
Sunshine Biopharma has a net margin of -12.82% compared to HCW Biologics' net margin of -1,067.82%. Sunshine Biopharma's return on equity of -17.89% beat HCW Biologics' return on equity.
Sunshine Biopharma has a consensus price target of $15.00, indicating a potential upside of 415.46%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than HCW Biologics.
3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 49.9% of HCW Biologics shares are owned by insiders. Comparatively, 0.1% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Sunshine Biopharma has higher revenue and earnings than HCW Biologics. HCW Biologics is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.
HCW Biologics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
HCW Biologics received 4 more outperform votes than Sunshine Biopharma when rated by MarketBeat users.
Summary
Sunshine Biopharma beats HCW Biologics on 11 of the 17 factors compared between the two stocks.
Get Sunshine Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBFM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sunshine Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:SBFM) was last updated on 1/22/2025 by MarketBeat.com Staff
